文献速递肿瘤 PET/CT放射性药物与辐射防护

可置入式γ探针用于早期宫颈癌放射性引导前哨淋巴结检测的可行性

Feasibility of a drop-in γ-probe for radioguided sentinel lymph detection in early-stage cervical cancer.
PubMed 文献 · EJNMMI Res · 2022-06-20

纳入10例FIGO IA-IB2或IIA1期宫颈癌患者,行术前240 MBq 99mTc纳米胶体注射及SPECT/CT,术中采用可置入式γ探针SENSEI®行前哨淋巴结检测并以常规硬质腹腔镜γ探针确认。可置入式γ探针总体检出率100%、双侧检出率80%,与硬质探针计数率无显著差异(p=0.69),无干预相关不良事件。

要点

  • 可置入式γ探针在早期宫颈癌机器人辅助前哨淋巴结检测中安全可行,总体检出率100%。
  • 可置入式γ探针双侧检出率80%,联合术前SPECT/CT后双侧检出率90%。
  • 可置入式与硬质腹腔镜γ探针计数率无显著差异(p=0.69),无干预相关不良事件。

核心结论

  • 作者认为,可置入式γ探针用于早期宫颈癌患者前哨淋巴结检测是安全且可行的。
  • 作者认为,使用可置入式γ探针可增强机器人辅助前哨淋巴结检测中的可操作性和手术自主性。

研究设计与样本

  • 纳入10例FIGO IA-IB2或IIA1期宫颈癌、计划行机器人辅助腹腔镜前哨淋巴结手术的患者。
  • 所有患者术前接受240 MBq 锝-99m(99mTc)纳米胶体注射及SPECT/CT显像。
  • 术中采用带系绳的可置入式γ探针SENSEI®(Lightpoint Medical Ltd, Chesham, UK)行探针引导前哨淋巴结检测,随后以标准硬质腹腔镜γ探针确认。
  • 评估前哨淋巴结检出率和解剖位置,并用外科医生问卷评估可用性。
  • 试验注册于荷兰试验注册库(Netherlands Trial Registry),NL9358,注册日期2021年3月23日。

主要发现

  • 所有患者均在可置入式γ探针引导下成功切除至少1枚前哨淋巴结,总体检出率100%。
  • 可置入式γ探针双侧前哨淋巴结检出率为80%。
  • 2例仅单侧检出者中,1例为主动脉分叉处非典型前哨淋巴结位置、仅SPECT/CT检出,另1例为一侧99mTc摄取失败。
  • 术前SPECT/CT联合可置入式γ探针的双侧检出率为90%。
  • 硬质γ探针总体和双侧前哨淋巴结检出率分别为100%和80%,与可置入式γ探针相似。

关键数值与推荐

  • 可置入式γ探针总体前哨淋巴结检出率100%(10例中所有患者至少检出1枚)。
  • 可置入式γ探针双侧前哨淋巴结检出率80%,联合术前SPECT/CT后双侧检出率90%。
  • 硬质γ探针总体和双侧前哨淋巴结检出率分别为100%和80%。
  • 可置入式与硬质腹腔镜γ探针计数率比较 p = 0.69。
  • 可置入式γ探针共检出21枚前哨淋巴结,包括全部3枚肿瘤阳性淋巴结。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimally invasive radioguided sentinel lymph node (SLN) procedures, increasingly performed with robot-assisted laparoscopy, can benefit from using a drop-in γ-probe instead of the conventional rigid laparoscopic γ-probe. We evaluated the safety and feasibility of a tethered drop-in γ-probe system for SLN detection in patients with early-stage cervical cancer. METHODS: Ten patients with FIGO stage IA - IB2 or IIA1 cervical cancer scheduled for robot-assisted laparoscopic SLN procedure were included. All patients underwent preoperative 240 MBq technetium-99m nanocolloid (99mTc) injection and SPECT/CT imaging. Intraoperatively the tethered drop-in γ-probe SENSEI® (Lightpoint Medical Ltd, Chesham, UK) was used for probe guided SLN detection, subsequently confirmed by the standard rigid laparoscopic γ-probe. Sentinel lymph node detection rates and anatomical SLN location were assessed. Surgeon questionnaires were used to assess usability. RESULTS: In all patients at least one SLN was successfully resected under guidance of the drop-in γ-probe (overall detection rate: 100%). Bilateral SLN detection rate with the drop-in γ-probe was 80%. Of the two patients with unilateral SLN detection only, one presented with an atypical SLN location at the aortic bifurcation that was detected only on SPECT/CT. The other patient had failed unilateral 99mTc uptake. Combined use of preoperative SPECT/CT and drop-in γ-probe resulted in a bilateral detection rate of 90%. Similar to the drop-in γ-probe, overall and bilateral SLN detection rate of the rigid γ-probe was 100% and 80%, respectively. No significant discrepancy existed between the count rate of the drop-in and rigid laparoscopic γ-probe (p = 0.69). In total 21 SLN's were detected with the drop-in γ-probes including all three tumor positive nodes. Because of wristed articulation of the robotic tissue grasper and possibility of autonomous probe control by the surgeon, maneuverability and control with the drop-in γ-probe were highly rated in surgeon questionnaires. No adverse events related to the intervention occurred. CONCLUSIONS: Sentinel lymph node detection with a drop-in γ-probe is safe and feasible in patients with early-stage cervical cancer. Use of the drop-in γ-probe enhances maneuverability and surgical autonomy during robot-assisted SLN detection. Trial registration Netherlands Trial Registry, NL9358. Registered 23 March 2021, https://www.trialregister.nl/trial/9358 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Baeten IGT, Hoogendam JP, Braat AJAT, et al. Feasibility of a drop-in γ-probe for radioguided sentinel lymph detection in early-stage cervical cancer. EJNMMI Res. 2022. PMID: 35723832. doi:10.1186/s13550-022-00907-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。